Fig. 5From: SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTsForest plots examining the outcome cardiovascular mortality in participants of 11 CVOTs. There is moderate heterogeneity in the analyses (I2 = 42% of borderline significance)Back to article page